Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

orward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations(unaudited)Three Months Ended March 31,Nine Months Ended March 31,2013201220132012REVENUES:

$
-$
23,996$
,361$
2,705OPERATING EXPENSES:Research and development

2,944,5874,705,6627,733,6709,683,112General and administrative

1,079,1971,344,8613,141,7513,473,990Total operating expenses

4,023,7846,050,52310,875,42113,157,102Loss from operations

(4,023,784)(6,026,527)(10,865,060)(13,094,397)OTHER INCOME (EXPENSE):Investment income


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Investor-Edge has ... (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: MDVN ... Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,549.23, down 0.33%, the Dow Jones Industrial Average declined ...
(Date:10/30/2014)... Global polyvinyl chloride (PVC) demand registered a significant ... especially in North America and Europe. However, the global ... a growing trend. , The largest chunk of the ... segment. In 2013, the key PVC application spheres included ... film. Moreover, the PVC was consumed in the production ...
(Date:10/30/2014)... October 30, 2014 On October ... Medicine Showcase in Chicago, leading applied stem cell ... Dr. Wade McKenna presented talks on New Techniques ... Surgical Applications For Stem Cells. , Dr. Riordan ... and the properties of AlphaGEMS that include: wound ...
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Rancho BioSciences Manually Curated TCGA Data Sets Available 2
... VEGAS, Oct. 21 Altogen Biosystems announced the release ... reagent ( http://www.altogen.com/mirna.php ) in the company,s popular in ... Kit. This reagent is also compatible for in vivo ... and small proteins. The company also offers custom encapsulation ...
... Mass., Oct. 21 Sermo ( http://www.sermo.com ), the ... Sermo Report titled, " Physician Participation in the ESA ... participation rates in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk ... to the results, 83% of Hematologists/Oncologists view the ESA ...
... Oct. 21 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... nationwide and internationally, is pleased to announce that Chairman, CEO ... Operations, will appear for one hour live on "Go Rogue ...
Cached Biology Technology:PEG-Liposome siRNA In Vivo Transfection Kit From Altogen Biosystems 2Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network 2
(Date:10/29/2014)... been blamed for increasing the risk of a ... history of schizophrenia, are widely accepted. Others, such ... parasite transmitted by soil, undercooked meat and cat ... new study by Gary Smith, professor of population ... School of Veterinary Medicine, used epidemiological modeling methods ...
(Date:10/29/2014)... York City on September 19, 2014, leading geneticist and ... of Genome Sciences and Medicine at the University of ... of Tel Aviv University, was awarded the 2014 Lasker-Koshland ... to her honorary degree from TAU, Prof. King was ... Medicine, and for the past 18 years she has ...
(Date:10/29/2014)... An innovative workflow reveals new research potential of the ... recently published article in the Biodiversity Data ... BOLD in tabular format and imported these into a ... Writting Tool (PWT). Data were used to study ... wasps from the Microgastrinae subfamily. , BOLD is originally ...
Breaking Biology News(10 mins):Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
... latest-generation DNA sequencing technology to become the first explorers ... "This project is one of the first attempts to ... than a single organism," says Nicole Gerardo, assistant professor ... we can understand how these ants have evolved to ...
... the Centers for Disease Control and Prevention (CDC) found ... by age of menarche and total number of lifetime ... over the course of a woman,s lifetime may influence ... this study are published in Cancer Epidemiology, Biomarkers ...
... We see the face of the Virgin Mary staring up ... portion of our meal for $37,000 on eBay. We believe in ... science offers a wealth of rational explanations for natural phenomena, we ... And we,ll even go to war to protect our delusions against ...
Cached Biology News:Landmark project to map genomics of complex ant systems 22 reproductive factors are important predictors of death from ovarian cancer 22 reproductive factors are important predictors of death from ovarian cancer 3Our 'caveman logic' embraces ESP over evolution 2
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
... Dunbar (1994) • This book describes ... methods for preparing samples for protein ... radiometric and bioluminescence-enhanced detection systems are ... the detection and characterization of glycoprotein ...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: